National health budgets for expensive orphan drugs: Gaucher disease in Israel as a model
Authors:
- Deborah ElsteinDEDeborah Elstein
- Avi IsraeliAIAvi Israeli
- Raul ChertkoffRCRaul Chertkoff
- Ari ZimranAZAri Zimran
- 1 July 2006
- journal article
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 37 (1) , 46-49
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Diagnosis of lysosomal storage disorders: current techniques and future directionsExpert Review of Molecular Diagnostics, 2004
- A model of neuronopathic Gaucher diseaseJournal of Inherited Metabolic Disease, 2003
- Cessation of enzyme replacement therapy in Gaucher diseaseGenetics in Medicine, 2002
- Management of neuronopathic Gaucher disease: A European consensusJournal of Inherited Metabolic Disease, 2001
- Withdrawal of enzyme replacement therapy in Gaucher's diseaseBritish Journal of Haematology, 2000
- Asymptomatic Gaucher Disease Implications for Large-Scale ScreeningGenetic Testing, 1998
- Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher diseaseQJM: An International Journal of Medicine, 1998
- Low‐dose high‐frequency enzyme replacement therapy for very young children with severe Gaucher diseaseBritish Journal of Haematology, 1993
- PREDICTION OF SEVERITY OF GAUCHER'S DISEASE BY IDENTIFICATION OF MUTATIONS AT DNA LEVELThe Lancet, 1989